|
|
|
|
Vol. 300, Issue 1, 305-313, January 2002
Department of Neuroscience, Merck Research Laboratories, West Point, Pennsylvania (D.J.P., J.F.H., P.J.H., M.A.J., E.V.L., P.J.M., D.M.P., M.A.S., J.B.W., Z.Z.); and Department of Molecular Genetics, Deltagen Incorporated, Menlo Park, California (M.L.)
| |
Abstract |
|---|
|
|
|---|
Mice deficient in the neurotensin (NT)-1 receptor (NTR1) were developed
to characterize the NT receptor subtypes that mediate various in vivo
responses to NT. F2 generation (C57BL6/Sv129J) NTR1 knockout (
/
)
mice were viable, and showed normal growth and overt behavior. The
/
mice lacked detectable NTR1 radioligand binding in brain, whereas
NTR2 receptor binding density appeared normal compared with wild-type
(+/+) mice. The gene deletion also resulted in the loss of NTR1
expression as determined by reverse transcription-polymerase chain
reaction and in situ hybridization. Intracerebroventricular
injection of NT (1 µg) to +/+ mice caused a robust hypothermic
response (5-6°C) and a significant increase in hot-plate latency.
These effects were absent in the
/
mice. Similar results were
obtained with i.p. injections of the brain-penetrant NT analog
NMe-Arg-Lys-Pro-Trp-Tle-Leu (NT-2, 1 mg/kg i.p.). NT-2 administration
also impaired rotarod performance in wild-type mice, but had no
effect on motor coordination in knockout mice. In vitro, NT and NT-2 at
30 nM caused predominantly contraction and relaxation in isolated
distal colon and proximal ileum, respectively, from +/+ mice, but no
responses were observed with tissues from
/
mice. A similar loss of
the contractile effects of NT was observed in the isolated stomach
fundus from the knockout mice. In vivo, NT-2 administration reduced
colonic propulsion substantially in wild-type mice. In contrast, NT-2
had no effect in NTR1 null mice, whereas the hypomotility effect of
clonidine was intact. These data indicate that NTR1 mediates several of
the central and peripheral effects of NT.
| |
Introduction |
|---|
|
|
|---|
Neurotensin (NT) is a
tridecapeptide that was initially discovered and sequenced almost 30 years ago (Carraway and Leeman, 1973
; Brown and Miller, 1982
). NT is
synthesized within neurons throughout the CNS and within endocrine-like
cells of the gastrointestinal tract (Carraway and Leeman, 1976
; Kitabgi
et al., 1976
) and is known to exert several effects at these sites,
including hypothermia (Bissette et al., 1976
; Nemeroff et al., 1977
),
analgesia (Clineschmidt et al., 1979
), and effects on gastrointestinal
motility (Kitabgi and Freychet, 1978
). Two G protein-coupled receptors
for NT have recently been cloned, NTR1 (or NTS1) (Tanaka et al., 1990
;
Vita et al., 1993
) and NTR2 (or NTS2) (Chalon et al., 1996
; Mazella et
al., 1996
; Botto et al., 1998
). These two receptor subtypes are 41%
identical at the amino acid level. A third receptor or binding site,
NTR3 (or sortilin or gp95), has recently been described as a non-G
protein-coupled receptor that binds NT with high affinity and
appears to function in hormone trafficking and/or neurotensin uptake
(Navarro et al., 2001
).
Despite the extensive study of NT over the years, the
precise functions mediated by the various NT receptor subtypes are
still unclear (Vincent et al., 1999
). Two NT antagonists,
2-{[1-(-7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino}adamantane-2-carboxylic acid (SR48692) and
2-{[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]amino}adamantane-2-carboxylic acid (SR142948A), have recently been described (Gully et al., 1993
,
1997
) that have contributed much to the understanding of NT physiology.
However, although SR48692 exhibits some selectivity (~10-30×) for
NTR1 versus NTR2 (Gully et al., 1993
; Chalon et al., 1996
; Botto et
al., 1998
; Vita et al., 1998
), neither compound has the selectivity to
be truly useful for defining the roles of the various NT receptor
subtypes. Levocabastine is known to have selective, high affinity for
the NTR2 (versus NTR1) receptor (Chalon et al., 1996
; Botto et al.,
1998
); however, it is unclear whether it possesses primarily NTR2
agonist or antagonist activity (Botto et al., 1997
, 1998
; Vita et al.,
1998
; Yamada et al., 1998
; Dubuc et al., 1999a
), and with its high
affinity for histamine H1 activity, has also not been very useful in
defining the roles of these receptor subtypes in vivo.
Accordingly, we have produced and characterized mutant mice deficient in NTR1 to begin to more clearly define the roles of the NT receptor subtypes, and report herein that the hypothermic, analgesic, impaired motor coordination, and gastrointestinal tissue motility effects of NT agonism are dependent on this receptor subtype.
| |
Materials and Methods |
|---|
|
|
|---|
Generation of NTR1 Null Mice
A construct for the targeted disruption of the mouse NTR1 gene (GenBank accession no. AB017027) was prepared by Deltagen, Inc. (Menlo Park, CA). Homologous recombination with this construct was predicted to result in the deletion of 457 nucleotides of the mouse NTR1 gene, which included the initiator methionine codon at nucleotide 8, and the introduction of a neomycin resistance gene. The deletion removes the first 150 amino acids of the 424 amino acid NTR1 protein. The targeting construct was introduced into the R1 embryonic stem (ES) cell line. Neomycin resistant ES cell colonies were screened for targeted integration of the construct by PCR and Southern blot analysis by using external probes. High-percentage chimeric NTR1 mice were bred with C57BL/6 mice at Deltagen, Inc. and tested for transmission of the mutant allele by using a PCR assay. Heterozygous F1 progeny were then interbred to generate F2 hybrid mice.
The R1 ES cell line used to generate the NTR1 mice is a hybrid derived from strains 129X1/SvJ and 129S3/SvImJ. Genotype analysis (Research Genetics, Huntsville, AL) of heterozygous and wild-type NTR1 mice by using the polymorphic marker D2 Mit346, located approximately 15 cM centromeric of the Ntr1 gene, is consistent with the targeted chromosome being derived from 129X1/SvJ, which is nonisogenic to the construct that was generated from a 129SVImJ genomic library. The mice used in these experiments weighed 25 to 30 g. All studies reported herein were conducted in accordance with the Guide for Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
Mouse NT Receptor Cell Lines
Mouse NTR1 and NTR2 cDNAs (Mazella et al., 1996
) encoding the
full-length receptors were isolated by PCR and subcloned into the
mammalian expression vectors pcDNA3 (Invitrogen, Carlsbad, CA) and
pIRES/puro (CLONTECH, Palo Alto, CA), respectively. The expression
constructs were transfected into CHO NFAT-
lactamase cells (Aurora
Biotechnology, San Diego, CA) with LipofectAMINE 2000 (Invitrogen) and the appropriate antibiotic was used for selection. Cells were sorted by fluorescence-activated cell sorting analysis into pools of approximately 20,000 to 40,000 cells to develop
a population of NT receptor expressing cells and single cells into a
96-well plate to generate clonal cell lines. Cell populations and the
clonal cell lines were expanded and assayed for functional response to
the appropriate agonist and for expression level by saturation binding
with radiolabeled neurotensin.
NT Receptor Expression Studies
RT-PCR Analysis of NTR1 mRNA Expression. Total brain Poly (A)+ mRNA was isolated from wild-type, heterozygous, and homozygous NTR1 knockout mice by using the QIAGEN Oligotex Direct mRNA Isolation kit (QIAGEN, Valencia, CA) according to the manufacturer's recommendations. RT-PCR was performed using SuperScript One-Step RT-PCR kit from Invitrogen), with 400 ng of poly (A)+ RNA as template and 1 pmol of 5' PCR primer specific for the mouse NTR1 sequence deleted in the targeting construct (CACTGTCATTACCACCTGG) together with 1 pmol of the 3' primer AGAAGAGAGCGTTGGTCAGC. PCR was carried out with the following parameters: denaturation at 94°C for 15 s, annealing at 60°C for 30 s, and extension at 72°C for 1 min for 40 cycles. The mouse glyceraldehyde 3-phosphate dehydrogenase gene was amplified using the CLONTECH 0.45-kb control amplifier set. Products were analyzed on a 0.8% agarose gel. The specificity of the NTR1-amplified products was confirmed by DNA sequence analysis.
Northern Blot Analysis of mNTR2 Expression.
Poly
(A)+ brain RNA, 7.5 µg, from wild-type,
heterozygous, and homozygous NTR1 knockout mice was fractionated on a
1% agarose/formaldehyde gel, transferred to Hybond-N, cross-linked,
and hybridized in Rapid-hyb solution (Amersham Biosciences, Inc.,
Piscataway, NJ) containing 2 × 106 cpm/ml
of radiolabeled probe for 3 h at 65°C. The mouse NTR2 receptor
cDNA probe corresponds to a 1.3-kb fragment containing the complete
reading frame of the mouse NTR2 receptor. Filters were washed at 65°C
in a solution containing 0.1× SSC and 0.1% SDS and analyzed by
autoradiography. Filters were stripped and reprobed for
-actin.
In Situ Hybridization.
Mouse NTR1 RNA probes were
synthesized in an in vitro transcription reaction with 1 µg of the
template DNA by using a kit from Roche Molecular Biochemicals
(Indianapolis, IN) (catalog no. 999644). The probes were labeled with
33P-UTP (
2500 Ci/mmol, 20 mCi/ml; Amersham
Pharmacia, Inc.). A 1300-bp cDNA fragment encoding the mouse NTR1
receptor was used as a template for synthesis of RNA probes. The
labeled RNA probes were purified by passing through a quick spin column
(catalog no. 1274015; Roche Molecular Biochemicals), and followed by
probe size reduction in a carbonate buffer (120 mM
Na2CO3, 80 mM
NaHCO3, pH 10.4) at 60°C. After alkaline
hydrolysis neutralization buffer (1:28, v/v) was added, the probes
were precipitated in ethanol, and the pellets were resuspended in
diethyl pyrocarbonate-treated water.
80°C until
use. A series of coronal sections of the brains, 10 µm of each, were
made with a Leica cryostat (model CM3050), fixed in 4%
paraformaldehyde in 0.1 M phosphate-buffered saline, pH 7.4, at 4°C
for 30 min. The sections were dehydrated through graded ethanol
solutions. Slides were then hybridized in Hybridization Cocktail from
AMRESCO (catalog no. 0973; Solon, OH), at a probe concentration
of 1 × 107 cpm/ml hybridization buffer,
overnight at 60°C in a humid chamber. After hybridization, slides
were treated with RNase A (20 µg/ml) for 30 min, 37°C, washed three
times in 0.1× SSC at 65°C, 30 min each, once in 0.1× SSC at 70°C
for 10 min, rinsed briefly in deionized H2O, and
air-dried. Autoradiography was carried out with Kodak Biomax MR film.
Radioligand Binding Studies.
CHO NFAT-
lactamase cells
transfected with mouse NTR1 (CHO-NTR1) and NTR2 (CHO-NTR2) receptors
were grown to confluence and dissociated using Hanks' based
dissociation solution (S-004-B; Specialty Media, Phillipsburg,
NJ) (10 ml/T162 flask) and centrifuged to precipitate. The
pellet was homogenized in 1 mM Tris, pH 7.4, 40 µg/ml bacitracin,
centrifuged, washed, and centrifuged again. Membranes were resuspended
by homogenization in cold storage buffer (50 mM Tris, pH 7.4, 40 µg/ml bacitracin), harvested, and aliquoted (0.5 or 1 ml/vial) for
storage at
70°C until the day of the binding experiment.
70°C until the day of
the binding experiment. The tissues were chopped into small pieces,
homogenized using a polytron in ice-cold Tris homogenization buffer,
and followed by a series of washes as described above for the cells.
The preparation of membranes from peripheral tissues included a
filtration through four layers of cheesecloth before the last
centrifugation. The final resuspension was done in storage buffer at
tissue concentrations of 1 g/15 ml for the brain and 1 g/5 ml for the
other tissues. The membrane suspensions were used immediately in the
binding experiments. For both cell and tissue preparations, protein
concentration was measured using SDS (2%) solubilized membranes with
the Micro BCA protein kit (23235; Pierce Chemical, Rockford, IL).
Competition binding studies were performed by incubating membranes at
the appropriate concentration with 200 pM (CHO-NTR1) or 1 nM (CHO-NTR2,
tissues) 125I-NT (NEX 198; PerkinElmer Life
Sciences, Boston, MA) for 30 min at room temperature in a final volume
of 250 µl, in the presence of 40 µg/ml bacitracin, 0.8 mM
o-phenanthrolene, 0.1% bovine serum albumin, and the
concentration of the compound to be studied. Saturation binding studies
were performed using 125I-NT over a concentration
range of 50 pM to 4 nM. Nonspecific binding was determined using 1 µM
NT, which caused the same level of maximal inhibition of binding as
NT-2 and other reference agents such as SR48692. In some incubations
with mouse peripheral tissue membranes, levocabastine was present at 10 µM to mask possible binding to NTR2. The assay was terminated by
rapid filtration on Filtermat A (1204-401, GF/C filter; PerkinElmer
Wallac, Gaithersburg, MD) pretreated for 90 min with 0.2%
polyethylenimine followed by three washes with cold 10 mM Tris, pH 7.4, containing 100 mM NaCl by using a Skatron Micro 96 harvester (Molecular
Devices, Sunnyvale, CA). Dried filters were counted in a PerkinElmer
Wallac betaplate 1205 scintillation counter. Analysis of the data for determination of IC50 values was performed using
the GraphPad Prism software (GraphPad, San Diego, CA) for one-site
(cloned mouse NTR binding) and two-site (mouse brain NTR binding)
analysis. Ki values were then
calculated for the individual sites using the equation
Ki = IC50/[1 + c/Kd).
Isolated Tissue Bath Studies
Two 1-cm segments of both proximal ileum and distal colon were removed from C57BL6/129J hybrid mice of each genotype and gender after CO2 anesthesia/euthanasia. The tissue segments were attached to a Gould-Statham force-displacement transducer and placed under 200-mg tension into 10-ml heated-jacket glass organ baths filled with physiological Tyrode's solution, pH 7.4 (37°C), and bubbled continuously with 95% O2, 5% CO2. After 60-min equilibration, the tissues were contracted once to acetylcholine (1 µM) to assess tissue viability, washed repeatedly over the next 60 min, and then exposed to either NT or NT-2 at 30 nM. These concentrations were determined in separate experiments to exert maximal effects. Contractile responses (mg of tension) were recorded and calculated as group means ± S.E.M.
Measurement of Core Temperature and Hot-Plate Analgesia
The effects of NT given i.c.v. (1 µg in 5 µl) or NT-2 given
i.p. (1 mg/kg) on core temperature and hot-plate analgesia were evaluated in C57BL6/129J hybrid mice of each genotype (approximately 20 weeks old) and gender, weighing 20 to 30 g. These doses of NT and
NT-2 were determined in pilot experiments to produce maximal effects in
control animals. Injection of NT (in phosphate buffer, pH 7.4) into the
lateral ventricle was done free-hand in conscious mice by using a
26-gauge needle with a 2.5-mm depth stop at a location in the head 2 mm
unilateral to the midline and just caudal to the ocular orbit.
Placement of the injection was verified in some cases by using
methylene blue as a marker in the dosing solution. At various times
after the i.c.v. or i.p. injections, core temperature was measured by
inserting a thermistor probe 2 cm into the rectum for about 5 s
and the temperature was recorded. At different times, the same animals
were tested for hot-plate reaction times by placing them gently into a
5-inch-diameter glass cylinder atop a metal plate maintained at 55°C
and recording the length of time for the animal to respond (i.e.,
flinch, lick a paw, or jump). The hot-plate test has been a test used
by several investigators to describe the analgesic actions of NT (Dubuc
et al., 1999a
; Tyler et al., 1998b
; Clineschmidt et al., 1979
). Data
were analyzed and plotted as group means ± S.E.M.
Motor Performance (Rotarod)
C57BL6/129J hybrid mice of each genotype and gender were trained on the morning of the test to remain on a Ugo Basile (Comero, Italy) rotarod apparatus for 2 min rotating at 12 rpm. Pretest (baseline) measurements were taken for the time the mice were able to remain on the rotarod accelerating from 4 to 40 rpm over a period of 5 min. The mice were then injected i.p. with NT-2 (1 mg/kg) and the accelerating rotarod test was repeated at 45 and 90 min later. Data were analyzed and represented as mean percentage ± S.E.M. pretest values.
Measurement of Colonic Propulsion
Colonic motility or propulsion was measured according to the
method of Pendleton et al. (1986)
. In these studies, C57BL6/129J hybrid
mice of each genotype and gender were injected i.p. with either NT-2 (1 mg/kg) or clonidine (100 µg/kg) by using 0.9% NaCl as vehicle. Five
minutes later, a 3-mm glass bead was inserted 2 cm rectally into mice
by using a glass syringe plunger. The number of mice in each group
(n = 20) expelling their beads at various time points
were recorded and expressed as a percentage. The doses of NT-2 or
clonidine were determined in pilot studies to be maximal doses. All
mice treated with vehicle consistently expelled their bead within 20 min.
Compounds
NT (neurotensin 1-13) was obtained from Peninsula Laboratories (Belmont, CA) and NT-2 was purchased from Neosystem, Group SNPE (Strasbourg, France). Clonidine was purchased from Sigma Chemical (St. Louis, MO).
Statistics
Significant differences (P value < 0.05)
between groups for all studies except the glass bead test were
determined using one-way analysis of variance followed by a Global F
test and pairwise comparisons with the least significant difference
method of Fisher (1958)
. For the glass bead test, significant
differences between groups at individual time points were determined
using a two-sided Fisher's exact test (Agresti, 1990
).
| |
Results |
|---|
|
|
|---|
General Phenotype of NTR1 Knockout Mice
F2 generation C57B6/129J hybrid +/+,
/+, and
/
NTR1 mice
were viable at birth and lived through at least 1 year of age. The
mutant genotypes matured with very similar, if not identical growth
rates, to the wild-type mice and had no obvious physical abnormalities.
Autopsy of three mice of each gender and genotype at 7 weeks of age
indicated no important effects of gene deletion on organ development
(gross and histological), serum chemistry, hematology (red blood cell
count, white blood cell count, hematocrit) (data not shown).
Expression of Neurotensin Receptor Subtypes in NTR1 Knockout Mice
RT-PCR and Northern Blot Analysis.
In preliminary experiments,
it was determined that NTR1 mRNA expression in whole brain was too low
for acceptable Northern blot analysis. Therefore, RT-PCR was used to
determine the mRNA expression in wild-type, heterozygous, and knockout
mice. A PCR primer pair was designed to preferentially detect the NTR1
coding sequences that were deleted in the targeting construct used to generate the knockout mice. The 779-bp product resulting from primers
against the deleted sequence was amplified from both wild-type and
heterozygous mouse mRNA, and was absent from knockout mice mRNA (Fig.
1A). No products were detected in the
absence of reverse transcriptase or in the absence of template for all
three genotypes. The identity of the amplified PCR products was
confirmed to be NTR1 by DNA sequence analysis.
|
, and
/
mice and
no difference in the level of expression was observed among the three
genotypes (data not shown).
In Situ Hybridization.
Adjacent brain coronal sections were
selected across the brains from wild-type and knockout mice (A-P
coordinates: bregma 1.00 mm and
3.4 mm) and hybridized with either
[33P]UTP-labeled antisense or sense NTR1 RNA
probes. In three pairs of sections from wild-type mice, the NTR1 mRNA
expression was revealed by in situ hybridization with an antisense RNA
probe. High intensity of hybridization signal was shown in several
brain regions, including the hippocampus, amygdala, hypothalamus, and cerebral cortex, particularly layers 5 and 6 (see Fig. 1B for representative image). In addition, moderate intensity of hybridization signal was also shown in the thalamic region (data not shown). In
contrast, no hybridization signal was detected in any of the sections
from the knockout mice (Fig. 1B). The sense RNA probe did not show any
significant hybridization signal in all adjacent brain sections from
either genotype (Fig. 1B).
Radioligand Binding Studies.
125I-NT
saturation studies indicated the presence of two populations of binding
sites in the wild-type brain: a high-affinity site (presumptive NTR1)
with a Kd = 290 ± 50 pM, and
Bmax = 22 ± 4 fmol/mg of
protein, and a low-affinity site (presumptive NTR2) with
Kd = 1900 ± 220 pM and
Bmax of 42 ± 11 fmol/mg of
protein (n = 3) (see Fig.
2 for representative experiment).
Competition of 1 nM 125I-NT binding by the
NTR2-selective drug levocabastine confirmed the existence of the two
sites in the brains of the +/+ and the +/
mice (Fig.
3). However, in the
/
NTR1 mice, only
one site was revealed (Figs. 2 and 3) with a
Ki for levocabastine of 22 nM,
consistent with its affinity for mouse NTR2 (Table
1). The experiment was repeated three
times and comparable results were obtained with the proportion of the
high-affinity site for levocabastine (NTR2) varying from 53 to 68% in
the wild-type and 60 to 75% in the heterozygous mice.
|
|
|
/
mouse tissues, no 125I-NT
specific binding was detected in the presence or absence of levocabastine.
Isolated Tissue Studies
The exposure of ileal and colonic segments from wild-type mice to
a single, maximal dose of NT at 30 nM caused transient, biphasic
relaxation/contraction responses. Cumulative dose-response curves could
not be conducted with NT because of tachyphylaxis. The predominant, and
most consistent, responses for the colon and ileum from +/+ mice were
contraction and relaxation, respectively, and the magnitude of these
effects is shown in Fig. 4. In contrast, tissues from knockout mice did not respond to NT (Fig. 4), whereas +/
tissues responded like +/+ tissues. The relaxation of colon and
contraction of ileum were relatively weak and variable and could not be
quantitated reliably, but qualitatively these responses were also
absent in the
/
mice (data not shown). Qualitatively similar
results were obtained with NT-2 (30 nM) in ileum and colon and for
contractile responses to NT (30 nM) in stomach fundus (data not shown).
Like NT, NT-2 shows high affinity for both mouse NTR1 and NTR2 with
about a 30× higher affinity for NTR1 (Table 1).
|
Behavioral Studies
Core Body Temperature and Hot-Plate Analgesia Studies.
The
i.c.v. administration of NT to wild-type mice caused a large drop in
body temperature of about 5-6°C at 45 to 90 min after a dose of 1 µg (Fig. 5A). Heterozygous mice
responded in a similar manner to wild-type mice, but knockout mice
exhibited no hypothermia over this time course (Fig. 5A). A similar
profile of responses was observed at 45 min after peripheral dosing of
NT-2 (1 mg/kg i.p.) where a 5-6°C drop in body temperature was
obtained in +/+ and +/
mice, but not in
/
mice (Fig. 5B). The
doses of NT and NT-2 used here were maximal, based on preliminary
dose-response studies in control mice (data not shown). Hot-plate
(55°C) reaction times were measured in the same animals as for core
temperature, but at different time points. Both NT (1 µg i.c.v.) and
NT-2 (1 mg/kg i.p.) caused significant increases in response latency
after placement on the heated surface at 30 and 60 min after dosing of
wild-type mice (Fig. 6, A and B). A
similar analgesic response was seen after NT or NT-2 dosing of
heterozygous mice, whereas no increase in response latency was observed
in the knockout mice. These studies were conducted with equal numbers
of male and female mice and no consistent effects of gender were
observed (data not shown). There were no significant differences in
baseline core body temperatures or hot-plate reaction times between the
three genotypes when duplicating the time course out to 90 min in
untreated animals (data not shown).
|
|
Motor Performance (Rotarod) Studies.
The mice of the three
genotypes showed no differences in their ability to remain on an
accelerating rotarod (Fig. 7A). Treatment of the mice with NT-2 at 1 mg/kg i.p. caused roughly a 50% reduction in the pretest performance of the +/+ and +/
mice at 45 and 90 min
(Fig. 7B). No loss in performance, however, was observed in the NTR1
knockout mice after NT-2.
|
Colonic Propulsion Studies.
NT-2 was tested in the three
genotypes for effects on colonic motility, as measured by the rate at
which a rectally placed glass bead was expelled. In mice of each gender
and genotype, all of the vehicle-treated mice expelled the bead within
20 min (data not shown). Treatment with NT-2 (1 mg/kg i.p.) inhibited the expulsion of the glass bead in 95% of the +/+ mice after 20 min, a
reflection of reduced colonic propulsion (Fig.
8A). This inhibition was partially and
gradually reversed over a 3-h time frame. Similar to vehicle-treated
wild-type mice, treatment of NTR1 knockout mice with NT-2 did not
result in any disturbance in colonic propulsion at any of the time
points measured, with all mice expelling the bead within 20 min. The
magnitude of inhibitory effect in +/
mice by NT-2 was intermediate,
suggestive of a gene-dose effect (Fig. 8A). In contrast, the inhibitory
effects of clonidine on colonic propulsion were similar for all three
genotypes (Fig. 8B).
|
| |
Discussion |
|---|
|
|
|---|
Upon central administration, NT and NT agonist analogs have been
shown over the years to produce a constellation of effects in rodents,
including hypothermia, analgesia, sedation, and antipsychotic-like activity (Bissette et al., 1976
; Nemeroff et al., 1977
; Clineschmidt et
al., 1979
; Nemeroff, 1980
; Kinkead et al., 1999
; Cusack et al., 2000
).
Most, if not all, of these CNS effects of NT can be mimicked by
systemic dosing of metabolically stable analogs of NT, most notably
NT-2 (Machida et al., 1993
; Sarhan et al., 1997
) and NT69L (Cusack et
al., 2000
; Tyler-McMahon et al., 2000
). NT is also known for its
pharmacological effects on certain peripheral functions, including
effects on intestinal motor and secretory activity (Kitabgi and
Freychet, 1978
), as well as certain effects on endocrine and
neuroendocrine function (Brown and Miller, 1982
).
Several receptor subtypes (NTR1, NTR2, NTR3) have now been cloned from
human and rodent species that are candidates for mediating the effects
of NT (Tanaka et al., 1990
; Vita et al., 1993
; Chalon et al., 1996
;
Mazella et al., 1996
; Botto et al., 1998
; Vincent et al., 1999
; Navarro
et al., 2001
). Attempts at defining the receptor subtype mediating two
prominent CNS effects of NT, hypothermia and antinociception, have not
provided a consistent picture. Although systemic dosing of SR48692
blocked centrally mediated NT-induced turning behavior, it failed to
alter NT-induced hypothermia and analgesia (Gully et al., 1993
; Dubuc
et al., 1994
), suggesting non-NTR1 (i.e., NTR2) involvement in these
responses to NT. A role for NTR2 in NT-induced analgesia (but not
hypothermia) was further suggested by Dubuc et al. (1999b)
by using an
NTR2 antisense knock-down strategy. On the other hand, use of peptide
nucleic acids to down-regulate NTR1 expression provided evidence for
involvement of NTR1 in the antinociception and hypothermia (Tyler et
al., 1998a
). Other studies showed that the highly NTR2-selective
levocabastine had no effect on baseline core body temperature or
NT-induced hypothermia or baseline analgesia (Tyler et al., 1998b
;
Dubuc et al., 1999a
), but either partially inhibited NT-induced
analgesia at low (but not high) doses (Tyler et al., 1998b
) or
completely blocked it (Dubuc et al., 1999a
). Peripherally, SR48692
blocks many of the motility effects of NT on intestinal tissue in vitro (Labbe-Jullie et al., 1994
; Croci et al., 1999
), suggesting mediation by NTR1. Complicating the interpretation somewhat, however, is the fact
that SR48692 is not highly NTR1 selective (versus NTR2) (Gully et al.,
1993
; Chalon et al., 1996
; Botto et al., 1998
; Vita et al., 1998
) and
in fact has significant affinity for NTR2 where it can act as an
agonist (Botto et al., 1997
; Vita et al., 1998
; Yamada et al., 1998
).
In the present article, we describe the generation of NTR1 knockout mice to study more clearly the functions of this receptor subtype. The gene deletion was accomplished by homologous recombination and was confirmed by RT-PCR, in situ hybridization, and radioligand binding. Although NTR1 expression was eliminated, the level of NTR2 expression appeared unchanged by Northern blot analysis and binding studies. These mice showed no obvious abnormalities by gross inspection, histologically or in overt behavior. Our studies with the NTR1 knockout mice, however, clearly indicate an important involvement of NTR1 receptors in several prominent effects of NT receptor stimulation in the CNS (hypothermia, hot-plate analgesia, and motor coordination based on rotarod performance) and on gastrointestinal function (colonic propulsion).
Intraventricular administration of NT to wild-type C57BL6/129J F2
hybrid mice caused a marked drop on core body temperature and, in
parallel, significant hot-plate analgesia, in agreement with other
studies in rats and mice (Nemeroff et al., 1977
; Clineschmidt et al.,
1979
; Dubuc et al., 1994
). These responses to NT, however, were
completely absent in the mutant mice in which the NTR1 gene had been
deleted. Like i.c.v. NT, the peripheral administration of the
metabolically stable, brain-penetrant NT analog NT-2 (Machida et al.,
1993
; Banks et al., 1995
) to wild-type mice also caused hypothermia,
hot-plate analgesia, and reduced rotarod performance in vivo, but again
these effects were absent in the NTR1 knockout mice. These results
substantiate the importance of NTR1 in these activities and confirm the
utility of these brain-penetrant NT analogs in studying the CNS actions
of NT (Pugsley et al., 1995
; Sarhan et al., 1997
; Tyler et al., 1999
;
Cusack et al., 2000
; Tyler-McMahon et al., 2000
).
The lack of effect of peripherally dosed SR48692 on NT-induced
hypothermia or analgesia reported elsewhere (Dubuc et al., 1994
;
Pugsley et al., 1995
; Gully et al., 1997
) would seem to be at odds with
the present findings implicating a role for NTR1 in these effects, but
some possible explanations may be offered for the discrepancy: 1) NTR2
agonist-like activity of SR48692 may somehow interfere with its NTR1
antagonist effects on these endpoints, or 2) effective free
concentrations of SR48692 in brain areas controlling the
hypothermic/analgesic effects on NT may not be reached after systemic
administration, in contrast to the striatum where systemic SR48692
exerted inhibitory effects on turning behavior stimulated by
intrastriatally dosed NT (Gully et al., 1993
). In addition, multiphasic
interactions have been noted recently for pain responses to various
doses of NT and SR48692 (Smith et al., 1997
), which may reflect the
complex ways in which these compounds can interact in vivo.
Our present results also show the role of NTR1 in gastrointestinal
function as well as the utility of NT-2 in studying peripheral mechanisms. NT-2 administration to wild-type mice reduced colonic propulsion, similar to the effects of clonidine (Pendleton et al.,
1986
). The effect to delay glass bead expulsion after NT-2 administration was absent in
/
mice, thus implicating a role of
NTR1. The hypomotility effects of clonidine on the colon, however, were
present in all three genotypes, indicating an otherwise normal colonic
response in these animals, at least to
2-adrenoceptor stimulation. The implied role
of NTR1 in the colonic response to NT-2 in the present studies is in
agreement with the interpretation of previous studies using SR48692,
implicating this receptor in various gastrointestinal motility
responses to NT (Labbe-Jullie et al., 1994
; Croci et al., 1999
),
although a potential role of NTR2 could not have been completely ruled
out given the NTR2 agonist activity of SR48692 (Botto et al., 1997
;
Vita et al., 1998
; Yamada et al., 1998
). The involvement of NTR1 in
gastrointestinal function is further exemplified by our in vitro
isolated tissue studies demonstrating loss of contractile and/or
relaxant effects in gastric, ileal, and colonic tissue taken from
/
mice.
The fact that several diverse effects of NT are eliminated in the
absence of NTR1 expression suggests that they may all be mediated
directly and independently by NTR1 receptors. Our results, however, do
not rule out that certain of the responses to NT may be dependent on,
or downstream of others. For example, it is not possible from our
studies to determine whether the effect of NT on hot-plate reaction
time is an independent effect, or one arising from the marked
hypothermia. Other investigators, however, have presented evidence that
the hypothermic and antinociceptive effects of NT are dissociable
(Clineschmidt et al., 1979
; Tyler et al., 1998c
; Dubuc et al.,
1999a
,b
).
In summary, these initial results with NTR1 knockout mice implicate a major role of NTR1 in mediating several of the well known central and peripheral effects of NT, including body temperature control, hot-plate analgesia, rotarod performance, and gastrointestinal motility effects. Additional study of these knockout mice will help define further the in vivo activities of NTR1, as well as possibly provide insights into the unknown physiological role(s) of NTR2 (and NTR3).
| |
Acknowledgments |
|---|
We thank Dr. Xiaoli Hou (Biometrics Research, Merck Research Laboratories) for expert assistance with the statistical analysis.
| |
Footnotes |
|---|
Accepted for publication October 1, 2001.
Received for publication August 22, 2001.
Address correspondence to: Dr. Douglas J. Pettibone, Department of Neuroscience, Building W46-300, Merck Research Laboratories, West Point, PA 19486. E-mail: doug_pettibone{at}merck.com
| |
Abbreviations |
|---|
NT, neurotensin; NT1R, neurotensin 1 receptor; ES, embryonic stem; PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; SSC, standard saline citrate; bp, base pair; CHO, Chinese hamster ovary; SR48692, {[1-(-7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carbonyl]amino}adamantane-2-carboxylic acid; SR142948A, 2-{[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]amino}adamantane-2-carboxylic acid.
| |
References |
|---|
|
|
|---|
2-adrenoceptor agonists upon colonic propulsion.
Drug Dev Res
9:
241-247[CrossRef].This article has been cited by other articles:
![]() |
V. A. Mitchell, H. Kawahara, and C. W. Vaughan Neurotensin inhibition of GABAergic transmission via mGluR-induced endocannabinoid signalling in rat periaqueductal grey J. Physiol., June 1, 2009; 587(11): 2511 - 2520. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sarret, M. J. Esdaile, A. Perron, J. Martinez, T. Stroh, and A. Beaudet Potent Spinal Analgesia Elicited through Stimulation of NTS2 Neurotensin Receptors J. Neurosci., September 7, 2005; 25(36): 8188 - 8196. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gendron, A. Perron, M. D. Payet, N. Gallo-Payet, P. Sarret, and A. Beaudet Low-Affinity Neurotensin Receptor (NTS2) Signaling: Internalization-Dependent Activation of Extracellular Signal-Regulated Kinases 1/2 Mol. Pharmacol., December 1, 2004; 66(6): 1421 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Belmeguenai, L. Desrues, J. Leprince, H. Vaudry, M.-C. Tonon, and E. Louiset Neurotensin Stimulates Both Calcium Mobilization from Inositol Trisphosphate-Sensitive Intracellular Stores and Calcium Influx through Membrane Channels in Frog Pituitary Melanotrophs Endocrinology, December 1, 2003; 144(12): 5556 - 5567. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||